Demographic and baseline clinical characteristics of patients with sarcoidosis associated pulmonary hypertension receiving treatment with sildenafil*
| Non-responders (n=10) | Responders (n=12) | p Value | |
| Age (years) | 53.5 (14) | 58.5 (10) | NS |
| Gender, M:F | 5:5 | 5:7 | |
| Follow-up (months) | 23 (16) | 20 (12) | NS |
| Baseline | |||
| mPAP (mm Hg) | 50 (10) | 43 (8) | NS |
| PaO2 (kPa) | 7.8 | 8.2 | NS |
| DLco % predicted | 20 | 34 | 0.03 |
| Kco % predicted | 46 | 62 | 0.05 |
| Δ BNP at 6 months | +21% | −51% | |
↵* Values are given as mean (SD) or median (range).